Skip to main content
Log in

Acute electroretinographic changes during Sildenafil (Viagra) treatment for erectile dysfunction*

  • Published:
Documenta Ophthalmologica Aims and scope Submit manuscript

Abstract

The authors describe their findings on 12 subjects who were treated with 50 mg of Sildenafil (Viagra) and underwent ERG measurements prior to and 1 hour after ingestion. The Naka–Rushton equation was used to describe the b-wave luminance-response function of the scotopic ERG. Statistically significant differences were noted in the V max and K values. Sildenafil ingestion resulted in an increase in V max (higher rod response to light stimuli) and a decrease in K (higher sensitivity).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fabbri A, Aversa A, Isidori A. Sildenafil and erectile dysfunction. J Endocrinol Invest 1999; 22: 486-92.

    Google Scholar 

  2. Center for Drug Evaluation and Research. A randomized, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral tablet dose of sildenafil (200mg) on visual function (electroretinogram, photostress, visual field and colour discrimination tests) in healthy male volunteers and patients with diabetic retinopathy: study 148– 232. In: Viagra (Sildenafil): Joint Clinical Review for NDA-20-895. Washington, DC: Center for Drug Evaluation and Research, Food and Drug Administration; 1998. Available at: http://www.fda.gov/cder/foi/nda/98/viagra/d efault.htm

    Google Scholar 

  3. Center for Drug Evaluation and Research. Phase I investigatorblind, placebo-controlled, evaluation of safety, toleration and pharmacokinetics of sildenafil following escalation single oral doses in healthy male volunteers: study 140–004. In: Viagra (Sildenafil): Joint Clinical Review for NDA-20-895. Washington, DC: Center for Drug Evaluation and Research, Food and Drug Administration; 1998. Available at: http://www.fda.gov/cder/foi/nda/98/viagra/default.htm

    Google Scholar 

  4. Marmor MF, Kessler R Sildenafil (Viagra) and Ophthalmology. Surv Ophthalmol 1999; 44: 153-62.

    Google Scholar 

  5. Vobig AM, Klotz T, Staak M, Bartz-Schmidt KU, Engelmann U, Walter P. Retinal side effects of sildenafil Lancet 1999; 353:375.

    Google Scholar 

  6. Marmor MF, Zrenner E, for the International Society for Clinical Electrophysiology of Vision.Standard for clinical electroretinography (1999 Update) This document was approved by the International Society for Clinical Electrophysiology of Vision in Eilat, Israel on April 15, 1999. Doc Ophthalmol (in press). Available at: http://www.iscev.org/aug/iscev/standards/er g1999.html

  7. Behn D, Potter MJ. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the γ-subunit of phosphodiesterase. Invest Ophthalmol Vis Sci 2001; 42: 523-27.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gabrieli, C.B., Regine, F., Vingolo, E.M. et al. Acute electroretinographic changes during Sildenafil (Viagra) treatment for erectile dysfunction* . Doc Ophthalmol 107, 111–114 (2003). https://doi.org/10.1023/A:1026271404384

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026271404384

Navigation